How can clinicians navigate emotionally complex patient interactions while maintaining empathy and trust? In this article, Mio Nakamura discusses communication approaches that may help strengthen patient relationships in dermatology settings.
Read summaries from the IPC symposium at the 2026 Society for Investigative Dermatology (SID) Annual Meeting covering disease modification, immune pathways, therapeutic escape, and psoriasis treatment response.
In this Take Ten with IPC video, Professor Peter van de Kerkhof discusses the use and misuse of systemic corticosteroids in psoriasis. He questions whether they contraindicate the treatment of psoriasis, while also covering his personal experience in prescribing them.
In this Take Ten with IPC video, Professor Peter van de Kerkhof discusses the use and misuse of topical corticosteroids in psoriasis, covering current use, guidelines, and consequences.
Missed the joint symposium hosted by the International Eczema Council (IEC) and International Psoriasis Council (IPC) at the American Academy of Dermatology (AAD) Annual Meeting? Select presentations from Psoriasis or Dermatitis? When Boundaries Blur and Treatments Flip the Script are now available, covering diagnostic overlap, emerging tools, treatment-related reactions, and practical strategies for managing complex cases across diverse patient populations.
Commentary: Sex differences in immune responses that underlie COVID-19 disease outcomes
Errol Prens, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands
IPC Councilor
PUBLICATION
Sex differences in immune responses that underlie COVID-19 disease outcomes. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, Silva J, Mao T, Oh JE, Tokuyama M, Lu P, Venkataraman A, Park A, Liu F, Meir A, Sun J, Wang EY, Casanovas-Massana A, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ; Yale IMPACT Research Team, Shaw A, Fournier JB, Odio CD, Farhadian S, Dela Cruz C, Grubaugh ND, Schulz WL, Ring AM, Ko AI, Omer SB, Iwasaki A. Nature. 2020 Dec;588(7837):315-320. doi: 10.1038/s41586-020-2700-3. Epub 2020 Aug 26. PMID: 32846427; PMCID: PMC7725931.
COMMENTARY
Because of the growing body of evidence indicating sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19) infection, the IMPACT Research Team from Yale University investigated sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients. They discovered essential differences in immune responses during the disease course of SARS-CoV-2 infection in male versus female patients. First, they found that the levels of important pro-inflammatory innate immune chemokines and cytokines such as IL-8, IL-18 (at baseline), and CCL5 (longitudinal analysis) were higher in male patients, which correlated with more elevated non-classical monocytes (at baseline) and more severe disease. Second, they observed a more robust T cell response among female patients than male patients at baseline. Collectively, their data suggest that vaccines and therapies to elevate T cell immune response to SARS-CoV-2 might be warranted for male patients. In contrast, female patients might benefit from therapies that dampen innate immune activation early during disease. The immune landscape in COVID-19 patients is considerably different between the sexes. They conclude that these differences may underlie heightened disease susceptibility in men.
The authors recognize an important limitation of their study: healthy healthcare workers who served as controls were not matched to patients based on age, BMI, or underlying risk factors. Despite their corrections for those confounders in their statistical analyses, residual confounding is not ruled out due to underlying risk factors not available for the healthcare workers’ controls. The limited sample size of this study is an explicit limitation.
Categories
Recent Posts
What Matters Most to People with Psoriasis? IPC Members Help Shape a Global Answer
IPC Symposium at the 2026 Society for Investigative Dermatology (SID) Annual Meeting: Disease Interception, Treatment Response, and Immune Escape in Psoriasis
Approaching Challenging Patient Interactions with Empathy
Also Read
First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
Managing Immune Checkpoint Inhibitor-Induced Psoriasis: Inference-Based Guidance for Safe Use of Systemic Therapies
This commentary from IPC Board Member Lluís Puig examines inference-based guidance for managing immune checkpoint inhibitor-induced psoriasis and discusses how biologics and targeted systemic therapies can be used safely alongside cancer immunotherapy.
Traditional Systemic Therapies in Pediatric Psoriasis: An International Real-World Study
Jason Hawkes provides expert commentary on an international multicenter study evaluating two-year drug survival, efficacy, and safety of acitretin, cyclosporine, and methotrexate in pediatric psoriasis patients.
Subscribe to the IPC Newsletter